
1. gut liver. 2018 nov 15;12(6):615-622. doi: 10.5009/gnl18115.

a program treat hepatitis b north korea: model antiviral therapy 
resource-poor setting.

lee au(1)(2), linton h(3), kilsby m(4), hilmers dc(2)(5).

author information: 
(1)department gastroenterology liver services, concord repatriation
general hospital, university sydney, australia.
(2)hepatitis b free, sydney, australia.
(3)christian friends korea, black mountain, nc, usa.
(4)global care partners, berrien springs, mi, usa.
(5)department internal medicine pediatrics, center space medicine,
baylor college medicine, houston, tx, usa.

despite well-proven, safe effective therapies hepatitis b infection, 
delivery treatment remains significant challenge resource-poor settings. 
geopolitical economic restrictions present additional difficulties in
providing care north korea. however, treatment patients chronic
hepatitis b remains top priority north korean ministry public
health international agencies working north korean hepatitis healthcare
facilities. working partnership, path created institute this
much-needed program. consortium united states australian humanitarian
non-governmental organizations along generous individual corporate
donors working concert local national health authorities have
succeeded establishing first hepatitis b treatment program north korea.
the essential elements program include renovation existing hepatitis
hospitals, access antiviral medications, establishment laboratory
facilities, creation medical documentation record-keeping, training of
local health care professionals, quarterly visits international volunteer 
physicians laboratory experts. management treatment decisions made
bilaterally. date, nearly 1,500 patients evaluated, 800
have started long-term antiviral therapy. envisioned this
program eventually managed funded democratic people's republic
of korea ministry public health. program's success demonstrates a
potential model delivery antiviral therapy patients suffering from
hepatitis b developing countries.

doi: 10.5009/gnl18115 
pmcid: pmc6254628
pmid: 30157545  [indexed medline]

